Bayer HealthCare supports Middle East, North Africa and Europe diabetes projects under the “Excellence across Borders” program

Leverkusen, 12-6-2013 — / — Bayer HealthCare supports local projects under the “Excellence across Borders” program in order to improve care of people with diabetes. Among the projects is a Diabetic School Awareness Program in the Kingdom of Saudi Arabia, which is planned to start in autumn this year. Additional activities such as an editorial project of a region wide diabetes magazine in the United Arab Emirates are currently being planned. The projects were just recently introduced by leading diabetes experts at the second “Excellence across Borders” conference in Moscow, Russia. The two-day panel exclusively held for “Excellence across Borders” experts was titled “Practical Solutions in the daily treatment of diabetes” and provided insight on the progress of different activities.
“Behind the ‘Excellence across Borders’ program stands a high-class team of diabetes experts. Together, we aim at raising awareness and managing the disease burden and I am proud to state that we have reached a lot within the last year,” said Gerd-Walter Rohm, initiator of “Excellence across Borders” at Bayer HealthCare. “Participants gain international know-how, relay the information to their home countries and thus contribute to improving local disease management strategies.”

The program was initiated in May 2012 in Dubai, United Arab Emirates, and aims at building up a network of excellence among diabetes experts in countries with high prevalence rates such as in the Middle East, North Africa or Europe. Although there is extensive knowledge on the management of the metabolic disorder, some countries do not benefit to the same extent from the current options. Leading diabetes experts are invited to exchange views, address regional differences, and develop local projects.

This year’s conference was hosted by Professor Dr. Alexander Dreval at the Regional Research Clinical Institute (MONIKI) in Moscow. Professor Dreval is working on a diabetes registry of the Moscow region which is being established with the help of specially designed software considering local conditions. A member of his study group, Professor Dr. Inna Misnikova, introduced local activities for the prevention of diabetes, as well as epidemiological studies conducted in Moscow County. By taking a closer look at the Lukhovitsky Central Regional Hospital in the Moscow region including its diabetes mobile unit, participants could also catch a glimpse at how local health service providers work in a more rural area.

Diabetic School Awareness Program, Saudi Arabia
The “Diabetic School Awareness Program” which is planned to be launched in autumn 2013 is an evaluation to improve knowledge about current options in the diagnosis, therapy, and prevention of diabetes in Saudi Arabia. Located in the Jeddah region, the project aims at addressing the younger population that constitutes about 70 percent of the total population. Healthcare professionals will visit local schools to assess diabetes prevalence rates, and to gain information such as on obesity and glucose intolerance among teenagers between the ages of twelve and eighteen years. The fieldwork will include screening students at ten to 14 schools representing different socio-economic backgrounds. Students will be educated in improving personal lifestyles through lectures, audio-visual aids and educational activities including science teachers and health workers within the school system.

About “Excellence across Borders”
Diabetes is one of the most common diseases globally. Improving the conditions for people living with the condition will undoubtedly be one of the most challenging health issues of the 21st century. According to the International Diabetes Federation (IDF), the prevalence of the metabolic disorder is especially alarming in countries of the Middle East and Northern Africa (MENA) region, with prevalence rates as high as 23 percent. In many areas, more than 50 percent of the people with diabetes remain undiagnosed. While European prevalence rates are much lower (about 7 percent), the rate of undiagnosed people remains high, with about 39 percent.(1)With “Excellence across Borders”, Bayer HealthCare actively promotes a country-specific approach in countries with still low awareness in broader part of the population by sharing knowledge and experience in excellence-oriented networks. Participants may learn from one another and become inspired and motivated to search for new local options in diagnosing, treating, and preventing diabetes in their home countries.

About Diabetes
The changes in lifestyle and nutrition that come along with modern societies enhance the risk of diabetes. The metabolic disorder occurs when the pancreas is unable to produce a sufficient amount of insulin, or when the body is not able to effectively use the produced insulin. In that case, an increased concentration of glucose in the blood (hyperglycemia) can seriously harm the body, particularly nerves and blood vessels. Diabetes can be caused by a genetic predisposition, as well as factors like obesity, physical inactivity, increasing age and even ethnicity.(2)

About Bayer HealthCare 
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at

Our online press service is just a click away:

Follow us on facebook:
Follow us on Twitter:

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

(1) International Diabetes Federation. Diabetes Atlas 2012.
(2) International Diabetes Federation,


Comments are closed.